Brain fog in Crohn's disease is measurable, and what gets measured is not intelligence. When researchers test people with inflammatory bowel disease against healthy controls, the deficits land in attention, executive function and above all working memory, the system that holds a few things in mind while you do something with them (Hopkins 2021). That is why the experience feels like reading a paragraph five times rather than like not understanding it.
What is genuinely unsettled is the cause. Inflammation, pain, sleep, anaemia, mood and medication all have evidence behind them, one careful study found the whole difference vanished once mood and education were accounted for, and a large 2026 systematic review still describes the results as controversial (Berrill 2013; Motisi Bertulli 2026). This article goes through each candidate, says what it would predict, and shows how to record the symptom so it survives a ten-minute appointment.
Is brain fog a recognised Crohn's symptom? Not formally, and that is the problem
Cognitive impairment is not on the established list of extraintestinal manifestations of inflammatory bowel disease. The classic sites are joints, eyes, skin, mouth and bile ducts, and our companion article on joint pain with Crohn's disease carries the shared explainer of what an extraintestinal manifestation is and which symptoms qualify. Brain fog is not in that table, and pretending otherwise would be inventing a category.
What the literature says instead is more tentative. The authors of the 2021 meta-analysis concluded that their findings suggest cognitive impairment is a potential extraintestinal manifestation of inflammatory bowel disease (Hopkins 2021). That single word is doing a lot of work, and it explains most of the frustration in the forums. A symptom sitting outside the recognised list does not get a screening question, a guideline paragraph or a slot on the clinic proforma, so it gets raised by the patient at minute nine of a ten-minute appointment and lands as an aside.
The same problem shows up in how it is talked about. A widely read thread in r/CrohnsDisease is titled, almost apologetically, "Is it brain fog or am I just dumb?" (r/CrohnsDisease thread). Underneath it, dozens of people describe losing capabilities they used to teach to other people. A separate thread is titled "GI ignoring exhaustion/brain fog as a symptom", and the replies are largely people saying they moved this particular conversation to their family doctor instead (r/CrohnsDisease thread).
That workaround is worth noticing, because it is rational. The blood tests, sleep assessment and mood screening that a cognitive complaint actually needs sit mostly in primary care, not gastroenterology. Framing the ask that way is more likely to work than asking a gastroenterologist to explain your concentration.
What "brain fog" turns out to mean when someone measures it
It means slowed, effortful processing in specific domains, with everyday memory for facts largely intact.
The strongest single summary comes from a systematic review and meta-analysis that screened 8,302 articles and included 12 studies covering 687 adults, 11 of them poolable. Compared with healthy controls, people with inflammatory bowel disease showed significant deficits in attention (standardised mean difference -0.36, 95% CI -0.60 to -0.12), executive function (-0.45, 95% CI -0.77 to -0.13) and specifically working memory (-0.58, 95% CI -0.85 to -0.30). Learning and recall was not significant (p = 0.089), and multidomain screening tools such as the Mini Mental State Examination showed no significant difference (-0.27, 95% CI -0.68 to 0.08, p = 0.14) (Hopkins 2021).
Four things follow from that, and they are all practically useful.
First, a standardised mean difference of -0.58 is a moderate effect, not a subtle one, but it is an average shift in a group. It does not tell you where you personally sit.
Second, the fact that screening tools found nothing while domain tests found something is the single most important detail in this literature. If your clinician runs a brief cognitive screen and it comes back normal, that is what the research would predict, and it does not mean nothing is happening. Those tools were built to detect dementia, not to detect a 10% slowing of working memory in a 38-year-old.
Third, the included studies were all cross-sectional, and they generally excluded people with active disease and older adults (Hopkins 2021). So this is a picture of relatively well, relatively young people. The group most likely to be reading this during a flare is the group least represented in it.
Fourth, the review was funded by the National Institute for Health Research, Crohn's and Colitis UK and the Medical Research Council, all public or charitable bodies, which is worth saying because it is unusual in this blog's citation list to be able to say it.
On what the symptoms feel like day to day, a 2026 study of 83 adults with inflammatory bowel disease using the perceived cognitive impairment items of the FACT-Cog recorded which symptoms occurred at least twice a week: trouble concentrating in 51.3%, forgetting names in 43.8%, forgetting an intended task in 38.9%, and slow thinking in 37.6% (Al-Saleh 2026). Those four are almost exactly the complaints the Reddit threads list, which is reassuring about both sources.
Does it track inflammation? The evidence disagrees with itself
Partly yes, in more than one dataset, and one of those datasets contradicts itself in a way nobody reporting it mentions.
The Crohn's-specific study everyone cites recruited 49 people with Crohn's disease and 31 age and sex matched controls, and used the Subtle Cognitive Impairment test, with response time as the primary measure. Response times were slower in Crohn's across all timepoints (p less than 0.001). In multivariate analysis, serum C-reactive protein, abdominal pain, plasma haemoglobin and concurrent fatigue were each independently associated with slower responses, with a trend for poorer sleep quality (p = 0.06) (van Langenberg 2017).
Then comes the part that is almost always dropped. In the same model, higher faecal calprotectin was associated with faster response times, not slower, with a coefficient of -1.77 (95% CI -1.79 to -1.76). The authors flagged it themselves as a conversely-directed finding. We cannot reconcile that with the CRP result, and neither, on the published abstract, could they. Two markers of the same disease process pointing in opposite directions within one regression is a reason to hold the inflammation explanation loosely, not a footnote. If you want the wider background on why a calprotectin number and how you feel come apart so often, that is the subject of high calprotectin but no symptoms.
An Israeli study took a different route. It screened 105 adults with Crohn's at routine follow-up, then gave a computerised battery to the 61 who either reported subjective cognitive complaints or scored 26 or below on a brief screen. Among those 61, the most commonly impaired domains were information processing speed (33%) and verbal function (28%). Crohn's disease activity index, a nutritional risk index derived from albumin and weight change, and haemoglobin all correlated significantly with the global cognitive score, and disease activity and nutritional risk stayed significant in regression independent of depression. The model explained 24% of the variance (Golan 2016).
Read those percentages carefully, because they are frequently misquoted. The 33% and 28% are shares of the pre-selected 61, the people who already reported a problem or screened low, not of the 105 recruited. And 24% of variance explained means three quarters of it was not.
A 2026 multicentre study looked at the other end of the age range: 356 adults aged 60 and over with inflammatory bowel disease across six American centres, using the Montreal Cognitive Assessment. At baseline 42% screened positive for cognitive impairment, with delayed recall and visuospatial function the most affected. At follow-up within a year, 31% improved and 19% worsened. After adjustment for age, race, education, depression, comorbidity count, disease type, duration and baseline score, symptomatically active disease at baseline was associated with worsening cognitive testing (adjusted odds ratio 3.01, 95% CI 1.20 to 7.50), and the relationship ran both ways: baseline deficits in delayed recall predicted symptomatically active disease at follow-up (adjusted odds ratio 2.22, 95% CI 1.10 to 4.47) (Kochar 2026). The population there is people over 60, which is not most of the people asking this question, and the study was funded by the National Institute on Aging.
And a small 2026 prospective study should temper all of it. Forty patients with inflammatory bowel disease and 42 controls had tablet-based cognitive testing before colonoscopy plus EEG monitoring during it. Adjusting for demographics, education and depression, EEG alpha power did not differ between groups, and median cognitive scores indicated moderate likelihood of impairment in both groups. The one difference was that controls improved on retesting 6 to 18 months later (p less than 0.01) while the inflammatory bowel disease group did not (p = 0.16) (Raje 2026). That is a null result on the primary comparison, and its most interesting finding, the missing practice effect, rests on 15 patients and 17 controls.
The study that found nothing
It deserves its own heading, because it is the best-powered study in the set and it is usually omitted.
An observational study recruited 231 participants, 150 with inflammatory bowel disease, 40 with irritable bowel syndrome and 41 healthy controls, and ran the Cardiff Cognitive Battery, a computerised set of tests covering psychomotor speed, memory and intelligence. Faecal calprotectin was measured to establish disease activity. People with inflammatory bowel disease did score significantly lower on fluid intelligence (p = 0.01) and crystallised intelligence (p = 0.028) than healthy volunteers. But when concurrent mood disorder and level of education were added as covariates, there was no significant difference between the groups. Neither disease duration nor disease activity affected cognitive function. The authors concluded that their results do not support an intrinsic disease process associated with cognitive dysfunction, and suggested concurrent mood disorders, particularly depression, as the more likely driver on specific tasks (Berrill 2013).
You should hold this study and the meta-analysis in your head at the same time. The meta-analysis pooled 11 studies and found domain-specific deficits. The largest single negative study says those deficits may be a shadow cast by mood and education. Both were done competently. The field has not resolved it, and a 2026 systematic review of 66 studies, 31 population-based, 13 genetic and 22 preclinical, still opens by describing the results as controversial (Motisi Bertulli 2026).
What the mechanism evidence actually shows
Two strands: inflammation can impair memory in humans directly, and brains in Crohn's look measurably different on imaging. Neither strand yet explains an individual's Tuesday.
The cleanest causal evidence is not from Crohn's at all. In a double-blind crossover experiment, 20 healthy male volunteers were given either a very low dose of endotoxin or saline and tested at 1, 3 and 9 hours. Endotoxin produced no physical sickness symptoms and no change in blood pressure or heart rate, only a 0.5 degree temperature rise, while raising TNF-alpha, interleukin-6, the interleukin-1 receptor antagonist and cortisol. Anxiety and depressed mood rose, and verbal and nonverbal memory performance fell significantly, with effect sizes of 0.55 to 0.64, and cytokine levels correlated with the size of the memory decrease (Reichenberg 2001). The population is 20 healthy young men, and the exposure is a single controlled immune stimulus, not chronic disease. What it establishes is the principle: immune activation alone, without feeling physically ill, is enough to measurably degrade memory in humans. That is the answer to anyone who says the fog must be secondary to something else.
On imaging, three studies are worth knowing, all small. A multimodal MRI study of 35 patients with Crohn's or ulcerative colitis and 32 healthy controls found increased activity and functional connectivity in cognitive and emotional processing regions including parts of the limbic system, basal ganglia and hypothalamus, increased amygdala and hypothalamus volumes, evidence of neurodegeneration in the putamen and pallidum, and increased hippocampal activity in those with active disease. Thalamic volume correlated positively with C-reactive protein. It was funded by the Canadian Institutes of Health Research (Goodyear 2023). A resting-state study of 35 people with Crohn's and 21 controls found no structural differences at all, but altered functional connectivity between the frontoparietal and salience networks and within the default mode network, and its authors described it as preliminary and hypothesis-generating (Kornelsen 2020). A third study of just 15 patients with Crohn's and 26 controls found altered spontaneous activity in the superior frontal gyrus, anterior cingulate cortex, supplementary motor area and left hippocampus (Li 2021).
Fifteen, thirty-five and thirty-five participants. Different methods, partly overlapping regions, one finding structural change and one explicitly not. This is a field at the stage of establishing that something is there, not at the stage of explaining your symptoms.
The causes worth checking, and what a normal result would and would not rule out
Here is each candidate, what it predicts, and how it gets tested. Bring this to a conversation rather than acting on it.
| Candidate | What it would predict | How it is usually checked |
|---|---|---|
| Active inflammation | Fog rises and falls with gut symptoms, CRP or calprotectin | CRP, faecal calprotectin, disease activity index (van Langenberg 2017; Golan 2016) |
| Poor or fragmented sleep | Worst on waking, better after a good night, insomnia present | Sleep history, insomnia severity, apnoea screening (Al-Saleh 2026) |
| Obstructive sleep apnoea | Snoring, unrefreshing sleep, daytime sleepiness, obesity or smoking | Sleep study; risk scores exist for this population (Hoffman 2022; Barnes 2023) |
| Anaemia | Breathlessness and pallor alongside the fog | Full blood count, ferritin; haemoglobin tracked with scores in two studies |
| B12 deficiency | Mostly relevant after substantial ileal resection | B12 with a confirmatory metabolite (Battat 2014) |
| Nutritional depletion | Weight loss, low albumin, restricted eating | Nutritional risk assessment (Golan 2016) |
| Corticosteroids | Onset with a steroid course, changes on withdrawal | Medication timeline (Judd 2014) |
| Depression or anxiety | Fog with low mood, anhedonia, rumination | Validated mood screening (Barberio 2021) |
| Something neurological | Sudden onset, focal signs, personality change | Urgent clinical assessment (Glenn 2025) |
A few of those rows deserve unpacking, because the forums get them backwards.
B12 is over-blamed. A systematic review of 42 articles covering 3,732 patients found that Crohn's disease in general, regardless of ileal location, did not increase the risk of B12 deficiency. Ileal resections greater than 30 cm were associated with deficiency, resections under 20 cm were not, and the 20 to 30 cm range was inconsistent. Ulcerative colitis did not predispose to deficiency at all. The authors also noted that every included study failed to use the confirmatory biomarker testing that diagnostic guidelines require, and that serum B12 alone is likely insufficient to diagnose deficiency (Battat 2014). A later prospective study in 66 people with Crohn's and 30 with ulcerative colitis found B12 below the reference range in 7.6% and 10%, but true deficiency, confirmed with elevated methylmalonic acid, in only 3% and 3.3% (Battat 2017). So a borderline B12 result is not the answer most people hope it is, and confirming it matters.
Iron is worth checking, and correcting it may not fix cognition. Every one of the threads we read contains advice to get ferritin tested, and that is reasonable for many reasons. But the one randomised trial we found that measured cognition after intravenous iron did so in 94 heart transplant recipients, not people with Crohn's, and found no statistically significant difference in cognitive change at six months between the 49 who received iron and the 45 who received placebo (Bürker 2025). A negative trial in a different population is weak evidence about Crohn's. It is still the best direct test of "fix the iron, fix the fog" that we could find, and it did not support it.
Sleep is probably where the most leverage sits. In the 2026 study of self-reported cognitive symptoms, 77% had poor sleep quality and 69.5% had clinically meaningful insomnia, and insomnia severity correlated moderately with trouble concentrating (rs = 0.51), slow thinking (rs = 0.46) and forgetting intended tasks (rs = 0.38) (Al-Saleh 2026). That study was funded by the Mayo Clinic, is cross-sectional, and cannot show direction.
The apnoea question is more concrete than most people expect. A large multi-network analysis found obstructive sleep apnoea in 7.8% of ulcerative colitis and 7.2% of Crohn's patients versus 4.3% of non-IBD patients, and inflammatory bowel disease remained an independent risk factor after controlling for age, race, sex, obesity, smoking, hypertension and diabetes (odds ratio 1.46, 95% CI 1.43 to 1.48) (Hoffman 2022). A separate survey of 670 adults with inflammatory bowel disease found 22.6% at moderate to high risk of apnoea on screening, with age, obesity, smoking and abdominal pain subscore in the model (Barnes 2023). Note the difference between 7.8% diagnosed and 22.6% at risk on a questionnaire: those are not the same quantity and should not be quoted as if they were. One of the r/CrohnsDisease replies we read came from someone who said they work as a sleep technician, urging the poster to get a sleep study. On the published evidence, that is one of the better-supported suggestions in the thread.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
Medication, including the one change that is not brain fog
Corticosteroids are the drug class with the clearest cognitive footprint. A review in the American Journal of Psychiatry reports that severe neuropsychiatric consequences, including suicide, suicide attempt, psychosis, mania, depression, panic disorder, delirium, confusion and disorientation, have been reported at 15.7 per 100 person-years at risk across all glucocorticoid courses and 22.2 per 100 person-years for first courses, and that the majority of patients experience less severe but distressing and possibly persistent changes in mood, cognition, memory or behaviour during treatment or withdrawal (Judd 2014). Those rates are across all indications, not Crohn's specifically. The withdrawal part matters, because it explains fog that starts as a course is tapering, when a patient assumes the drug is out of the picture.
Nothing here is a reason to alter a steroid course. It is a reason to write down when the course started and stopped alongside your fog counts, so the overlap is visible instead of remembered.
Mood, and why naming it is not a dismissal
Depression and anxiety are common in inflammatory bowel disease and they genuinely do affect cognitive test performance. A systematic review and meta-analysis of 77 studies including 30,118 patients found a pooled prevalence of anxiety symptoms of 32.1% (95% CI 28.3 to 36.0) and of depression symptoms of 25.2% (95% CI 22.0 to 28.5), with substantial heterogeneity, and higher rates in Crohn's than ulcerative colitis where both were measured in the same population (Barberio 2021).
Put that next to the negative study. If a quarter to a third of people with this disease have clinically significant mood symptoms, and mood symptoms degrade performance on attention and memory tasks, then some of the group-level cognitive difference genuinely is mood (Berrill 2013). That is not the same as "it is all in your head", for two reasons. Mood symptoms are a real consequence of living with an unpredictable illness, and the endotoxin experiment shows immune activation can degrade memory without any mood pathway at all (Reichenberg 2001).
Practically: screening for mood is not the clinician dodging you. It is one of the few steps with a treatment attached. What you want to avoid is mood being the only thing looked at, which is where a written record of the pattern helps, because fog that is worst in flares and absent in remission looks different from fog that has been constant for three years.
Does Crohn's disease increase dementia risk? Observational data and genetics disagree
This is the question underneath a lot of the fear, and the honest answer has two halves that point in different directions.
The observational half. A 2025 systematic review and meta-analysis of 10 population-based studies covering 7,895,339 participants, of whom 269,387 had inflammatory bowel disease, pooled eight studies and found a significant association with dementia risk (odds ratio 1.17, 95% CI 1.08 to 1.27). There was no significant association with Alzheimer's disease specifically (1.15, 95% CI 0.98 to 1.36). Stratified by type, both ulcerative colitis (1.15) and Crohn's disease (1.26, 95% CI 1.11 to 1.43) were positively associated. The authors stated plainly that current evidence is insufficient to establish causation (Peng 2025).
The genetic half. A 2025 triangulation study combined a meta-analysis of 10 observational studies with Mendelian randomisation, a design that uses inherited genetic variants as a natural experiment and is therefore much harder to confound. The observational arm found an association with dementia (risk ratio 1.36, 95% CI 1.04 to 1.78) and with vascular dementia in a single study, but not with Alzheimer's disease. The Mendelian randomisation found no causal association with dementia (odds ratio 1.01, 95% CI 0.98 to 1.03), Alzheimer's (0.98) or vascular dementia (1.02), and genetic correlation and co-localisation analyses found no genetic link either. The authors concluded the observed increase may reflect unobserved confounding or detection bias (Liu 2025). An independent two-sample Mendelian randomisation study using the International IBD Genetics Consortium and FinnGen data, validated against UK Biobank, reached the same null conclusion, with no effect in either direction (Liao 2024).
Detection bias is worth explaining, because it is probably the most important idea in this section. People with a chronic illness see doctors constantly. Cognitive problems in someone attending clinic four times a year are more likely to be noticed, investigated and coded than the same problems in someone who sees nobody. That alone can manufacture an odds ratio of 1.17 out of nothing.
There is also a 2025 Swedish nationwide cohort research letter whose title states that inflammatory bowel disease is linked to accelerated cognitive decline in individuals who already have dementia (Mo 2025). No abstract is available in PubMed or Europe PMC and we could not read the full text, so we cite it only for the existence of that analysis and deliberately quote no figures from it. It is a different question from whether the disease causes dementia, and it applies to a population most readers here are not in.
What all of this means for a 35-year-old with Crohn's and a foggy Tuesday: a relative risk of around 1.17, unsupported by genetic evidence, at an age when absolute dementia risk is very low, is not the explanation for your symptom. The 2026 systematic review that read 66 studies did conclude that biologics may potentially mitigate neuroinflammation-related decline, while calling explicitly for longitudinal studies and randomised trials to clarify it (Motisi Bertulli 2026). Potentially and needs clarifying are the operative words, and nobody should reframe that as a reason a particular drug will protect their brain.
The ADHD theory that fills the threads
In the r/CrohnsDisease thread that asks whether it is brain fog or stupidity, a striking number of replies describe an adult ADHD diagnosis arriving in their thirties or forties and reorganising their understanding of everything (r/CrohnsDisease thread). One reply goes further and states that ADHD is being studied as an autoimmune disease.
The population data do not support inflammatory bowel disease raising ADHD risk. A Danish nationwide register study of 3,559 people with paediatric-onset inflammatory bowel disease, matched 1:5 to 17,795 reference individuals, found an increased risk of depression (hazard ratio 1.50, 95% CI 1.26 to 1.80) and of antidepressant use (1.54), with the depression signal strongest in Crohn's disease (1.73). For ADHD it found the opposite of the forum theory: a reduced rate of methylphenidate use (hazard ratio 0.75, 95% CI 0.58 to 0.98), and in ulcerative colitis a reduced rate of ADHD diagnosis that did not reach statistical significance (Kappel 2024). The authors themselves called the finding surprising. Prescription data are an imperfect proxy for diagnosis, and this was paediatric-onset disease in one country, so it does not close the question. It does mean nobody should tell you that Crohn's explains an ADHD diagnosis.
Separately, a 2026 Danish registry study going the other direction found that among 785 patients with inflammatory bowel disease plus ADHD or autism versus 6,729 with inflammatory bowel disease alone, the combined group had a slightly higher 10-year cumulative incidence of severe disease activity (36.2% versus 33.7%), a higher risk of advanced therapies (adjusted hazard ratio 1.2, 95% CI 1.0 to 1.3), and in ulcerative colitis a higher colectomy risk (1.4, 95% CI 1.0 to 1.8). That study lists Ferring Pharmaceuticals and Takeda Pharma among its funders alongside a private foundation (Jansson 2026). The effects are small and the confidence intervals touch 1.0.
The useful version of this for you: two conditions can coexist, and if inattention has been lifelong rather than arriving with your diagnosis, that is worth raising with your GP on its own merits. What you should not do is let either label absorb the other. Fog that started with your disease and moves with flares is not the same story as difficulty concentrating since primary school.
Probiotics, SIBO and the claim you will meet within five minutes of searching
One study is the origin of nearly every "probiotics cause brain fog" post, and it is both interesting and disputed.
Researchers evaluated 30 patients with brain fogginess, gas and bloating, an intact gut and negative endoscopic and radiological tests, plus 8 without brain fogginess. Small intestinal bacterial overgrowth was more prevalent in the brain fog group (68% versus 28%, p = 0.05) and D-lactic acidosis much more so (77% versus 25%, p = 0.006). In the brain fog group, all participants were consuming probiotics. Symptoms were reproduced in 20 of 30, and after discontinuation of probiotics plus a course of antibiotics, brain fogginess resolved and gastrointestinal symptoms improved significantly in 23 of 30 (Rao 2018).
Three caveats, in order of importance. The population had an intact gut and no diagnosed inflammatory bowel disease, so it is not a Crohn's study. The intervention was two things at once, stopping probiotics and taking antibiotics, so the design cannot tell you which one mattered. And it was publicly contested: a rebuttal in the same journal argued explicitly that probiotics are not the cause (Quigley 2018). For inflammatory bowel disease specifically, the only work we could find on brain fog and probiotics is a 2021 conference abstract with no readable results, so we cite it purely for the fact that someone has looked (Apaar 2021).
If you are taking a probiotic and wondering about it, that is a conversation for your team, particularly because bacterial overgrowth after antibiotics is also a documented look-alike for a flare. Our article on SIBO versus IBS symptoms covers the overgrowth question and the limits of the testing.
How to record something a clinician cannot see
Stop rating the feeling and start counting the episodes. That is the single change that makes this discussable.
The reason is structural. Your clinician cannot observe your working memory, cannot verify "bad brain fog", and has no threshold to compare a 6 out of 10 against. What they can work with is a count, a duration and a co-occurrence. The published research has already picked the format for you: episodes per week and typical episode length are exactly what the brain fog validation study reported (Knowles 2024), and the symptom-level items used in this population are concrete behaviours, not adjectives (Al-Saleh 2026).
Record four things per day, which takes under a minute:
- Whether you had a fog episode, and roughly how long. Not severity. Presence and duration.
- Which symptom it was. Trouble concentrating, losing a word, forgetting an intended task, or slow thinking. Use the same four labels every time so they can be counted.
- What your gut was doing. Stool frequency, urgency, pain. This is the column that lets anyone test the inflammation hypothesis in your case.
- Sleep. Hours, and whether you woke. Given how strongly insomnia severity correlated with the same three cognitive symptoms, leaving this out wastes the exercise (Al-Saleh 2026).
Add two context notes rather than daily entries: any steroid course with start and stop dates, and any medication change. That is what turns an ambiguous pattern into a timeline.
If you would rather not build this yourself, Clairop is designed around exactly this shape of problem: logging symptoms, meals, stool and sleep in a few taps, then producing a summary you can take to an appointment. It is free to download, and it does not diagnose anything.
For the handover itself, do not print six weeks of raw rows. Our article on the symptom tracker for doctor problem covers what clinicians will and will not read and how to compress it onto one page, and how to prepare for a GI appointment covers the run-up. One useful extra: a fatigue management guideline for inflammatory bowel disease already exists, proposing a structured "fatigue attention cycle" for identifying and evaluating severely fatigued patients (Kreijne 2016). Naming a published framework is a good way to move a conversation from "I feel foggy" to "there is a process for this".
If you want specific wording to use in the room, the questions in what to ask your doctor about Crohn's disease can be adapted, and the mechanics of interpreting an activity score are in Harvey-Bradshaw Index interpretation.
A worked example: six weeks, two patterns
Two people with Crohn's disease keep the same four columns for six weeks. The counts are illustrative, not from a study.
Person A logs 22 fog episodes across 42 days, averaging around two hours. Nineteen of the 22 fall in a three-week stretch when stool frequency was up and they had abdominal pain on most days. Sleep was 6 to 7 hours throughout with no night waking. In the fortnight after their disease settled, they logged two episodes.
What that pattern supports is the inflammation-and-pain story, which is the association found in Crohn's specifically (van Langenberg 2017). The conversation it makes possible is about disease control, and a calprotectin or CRP alongside those dates is worth having. What it does not prove is causation in one person, and the calprotectin result may not cooperate, for the reasons above.
Person B logs 26 episodes spread evenly across all six weeks, with no relationship to stool frequency, which stayed at one or two formed stools a day. Sleep averaged 5.5 hours with waking two or three times most nights. Their worst fog days follow their worst sleep nights almost exactly, and they mention snoring.
That pattern points at sleep first, and the apnoea evidence in this population makes that a concrete request rather than a vague one (Hoffman 2022; Barnes 2023). Person B also, on their record, may be in remission with a persistent symptom, and pushing for escalated IBD treatment on the strength of the fog alone is unlikely to help. For whether their gut symptoms represent a flare at all, how to tell if you are in a Crohn's flare is the relevant read.
Same complaint, same six weeks of data, two completely different next steps. Neither would have been visible from the sentence "I have terrible brain fog".
What people ask about work, and what is honest to say
Nothing in this literature supports promising anyone their cognition will return to how it was. What it does support is that the symptom has measurable components, that several of those components have something attached to them, and that disease activity is one of them in more than one dataset (Golan 2016; Kochar 2026).
In the threads, the people who described the hardest time were in analytical jobs: programming, statistics, mathematics, detail-checking. That makes sense given which domains the testing implicates, because working memory is the resource those jobs run on. Several described rechecking work repeatedly, taking short naps, or restructuring their day around their better hours. Those are adaptations, not treatments, and they are worth writing down too, because "I now check my work three times and still miss things" is a functional impact a clinician can act on in a way that "brain fog" is not. The same principle applies outside the clinic: describing the cost and the recovery time rather than the feeling is what stops the conversation ending in "I'm tired too", which is the subject of how to explain Crohn's fatigue to people. If the work consequences are becoming the main problem, how to keep a job with Crohn's disease deals with that side.
One more honest note. Fog during a period of remission is common enough in these threads to be its own genre, and it is not evidence that you are secretly flaring. Symptoms persisting in remission are well documented more broadly, as covered in ulcerative colitis symptoms while in remission, and the Crohn's fatigue literature describes the same thing. A comment in one thread insisted that anyone with fog cannot be in full remission. That is a guess, and the published data on symptom and inflammation discordance do not support stating it as fact.
Myths worth retiring
"94% of people with IBD get brain fog, so it is basically universal." That figure is real and it comes from a self-selected online survey of 170 adults recruited to a study about brain fog, 85.9% of them female (Knowles 2024). It is the ceiling of a motivated sample.
"If cognitive screening came back normal, nothing is wrong." Multidomain screening tools showed no significant difference between groups in the meta-analysis, while attention, executive function and working memory did (Hopkins 2021). A normal brief screen is the expected result.
"It is definitely the inflammation." In the Crohn's-specific study, CRP was associated with slower responses while higher faecal calprotectin was associated with faster ones (van Langenberg 2017). And the largest single study found the group difference disappeared once mood and education were accounted for (Berrill 2013).
"It is definitely just depression." Immune activation alone degraded verbal and nonverbal memory in healthy volunteers with no physical sickness symptoms (Reichenberg 2001). Mood matters and it is not the whole story.
"Get your B12 up and it will clear." Crohn's in general, including ileal disease, did not raise deficiency risk, and confirmed deficiency was around 3% in a prospective study (Battat 2014; Battat 2017). Worth checking, rarely the answer.
"An iron infusion will fix your concentration." The one randomised cognitive test of intravenous iron we found, in heart transplant recipients, showed no significant cognitive change at six months versus placebo (Bürker 2025). Correct a deficiency because it needs correcting, not on that promise.
"Crohn's gave me ADHD." A nationwide cohort found reduced, not increased, methylphenidate use in paediatric-onset inflammatory bowel disease (Kappel 2024). Both can be true of one person; the disease is not the explanation.
"IBD causes dementia." Observational pooling gives around 1.17, two Mendelian randomisation analyses give nothing, and no association with Alzheimer's disease specifically was found in either (Peng 2025; Liao 2024; Liu 2025).
"Brain fog is a recognised extraintestinal manifestation." It is described in the literature as a potential one (Hopkins 2021). Saying it is established overstates the case, and our joint pain article sets out what the recognised list actually contains.
When to see a doctor promptly
Brain fog in Crohn's is usually gradual, fluctuating and worse when you are tired or flaring. Anything that does not fit that description deserves assessment rather than a tracker.
Seek urgent, same-day care for sudden confusion, new weakness or numbness on one side, new visual loss or double vision, new difficulty speaking or understanding speech, a marked change in personality, a first seizure, or cognitive change that has worsened steadily over days to weeks. On natalizumab or other immunosuppressive treatment, this matters more, not less (Glenn 2025).
See a doctor promptly for new or worsening blood in your stool, unexplained weight loss, fever, night-time waking with bowel symptoms, breathlessness or pallor suggesting anaemia, new or worsening abdominal pain, symptoms that began after the age of 50, or a family history of bowel cancer or inflammatory bowel disease that has not been discussed. See a doctor promptly if fog is arriving alongside any of these, because the priority becomes the red flag, not the cognition.
Book a routine appointment if fog is persistent and affecting work, study or safety, or if you have never had bloods, sleep and mood looked at together. Ask for the bundle rather than one test, and bring the counts. If cognitive symptoms are being dismissed outright, how to prepare for a GI appointment has the structure for making an under-recognised symptom land.
The honest bottom line
Brain fog in Crohn's disease is real and measurable. On objective testing the deficits sit in attention, executive function and working memory, they are moderate in size at group level, and they are invisible to the brief screening tools most clinics would reach for (Hopkins 2021).
Beyond that, be suspicious of confidence. Disease activity, systemic inflammation, abdominal pain, haemoglobin, fatigue and poor sleep all show associations, while the calprotectin finding in the Crohn's-specific study runs the wrong way, and the largest single study found the effect dissolve once mood and education were controlled (van Langenberg 2017; Berrill 2013). A 2026 systematic review of 66 studies still calls the picture controversial (Motisi Bertulli 2026). Anybody offering you a single cause is going beyond the evidence.
The dementia question resolves more cleanly than the fear suggests: a modest observational association, no causal signal in two genetic analyses, and no association with Alzheimer's disease specifically (Peng 2025; Liu 2025; Liao 2024).
So the practical answer is not a supplement and not reassurance. It is a record: episodes per week, typical duration, which of the four symptoms it was, what your gut was doing, and how you slept, with your steroid courses and medication changes marked on the timeline. That record is what turns an unmeasurable complaint into something your team can test hypotheses against, and it is the difference between being told it is stress and being asked for a sleep study.
You are not imagining it, and you are not losing your intelligence. You are describing a symptom the research has started to measure and has not yet explained.
